+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cell & Gene Therapy Clinical Trials Market by Therapy Type, Vector Type, Cell Type, Indication, Trial Phase - Global Forecast to 2030- Product Image
Cell & Gene Therapy Clinical Trials Market by Therapy Type, Vector Type, Cell Type, Indication, Trial Phase - Global Forecast to 2030- Product Image
Sale

Cell & Gene Therapy Clinical Trials Market by Therapy Type, Vector Type, Cell Type, Indication, Trial Phase - Global Forecast to 2030

  • PDF Icon

    Report

  • 181 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5666050
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The cell and gene therapy clinical trials market is evolving rapidly, shaped by technological innovation and increasing global participation. Senior leaders require actionable insights to navigate emerging complexities and competitive shifts with confidence.

Market Snapshot: Cell & Gene Therapy Clinical Trials

The Cell & Gene Therapy Clinical Trials Market grew from USD 10.48 billion in 2024 to USD 12.08 billion in 2025. It is projected to expand at a CAGR of 14.76%, reaching USD 23.95 billion by 2030. This robust growth reflects a convergence of scientific progress, transforming clinical operations and opening new global opportunities for stakeholders.

Scope & Segmentation

  • Therapy Types: Includes cell therapy (such as CAR T cell, dendritic cell, NK cell, and stem cell therapies), gene therapy (non-viral vectors like electroporation, lipid nanoparticle, naked DNA/RNA; viral vectors such as adeno-associated virus, adenoviral, and retroviral), and tissue engineered products.
  • Vector Types: Covers non-viral options (electroporation, lipid nanoparticles, naked DNA/RNA) and viral vectors (adeno-associated, adenoviral, and retroviral systems).
  • Cell Types: Encompasses dendritic cells, NK cells, stem cells (hematopoietic, mesenchymal), and T cells (CAR T, TCR-based approaches).
  • Indications: Spans neurology (including Alzheimer’s and Parkinson’s), oncology (hematologic—leukemia, lymphoma, solid tumors—breast cancer, melanoma), and rare diseases (genetic disorders like cystic fibrosis, hemophilia, and metabolic disorders).
  • Trial Phases: Considers growth and activity distributed across Phase I, Phase II, and Phase III clinical programs.
  • Geographic Regions: Americas (United States—key states, Canada, Brazil, Mexico, Argentina); Europe, Middle East & Africa (including UK, Germany, France, Russia, regional hubs); Asia-Pacific (China, Japan, Australia, India, South Korea, and more).
  • Leading Companies: Features Novartis AG, Gilead Sciences, Inc., Spark Therapeutics, Inc., bluebird bio, Inc., Sangamo Therapeutics, Inc., CRISPR Therapeutics AG, Editas Medicine, Inc., Fate Therapeutics, Inc., Orchard Therapeutics Ltd, uniQure N.V.

Key Takeaways for Senior Decision-Makers

  • Market momentum is driven by advanced cell and gene editing technologies, with a fundamental shift toward precision, patient-centric approaches in trial design.
  • Operational changes—like adoption of modular manufacturing and remote monitoring—are enhancing scalability, consistency, and geographic reach of clinical programs.
  • Regional hubs, especially the United States, Western Europe, and East Asia, continue to shape trial site selection and regulatory dynamics, prompting strategic regional alignment.
  • Strategic alliances—spanning academic institutions, contract providers, and technology innovators—empower organizations to address clinical development complexity and accelerate progress.
  • Diversification across vectors, cell types, and disease targets supports broader portfolio resilience, with special emphasis on oncology and rare disease research.
  • Investments in talent development and digital data management are increasingly critical for sustaining innovation and meeting evolving compliance benchmarks.

Tariff Impact and Supply Chain Considerations

Forthcoming US tariffs on imported raw materials and biologics manufacturing inputs are expected to create cost and supply chain challenges for trial sponsors in early 2025. Organizations are proactively exploring domestic sourcing, nearshoring, and strategic partnerships with contract development and manufacturing organizations to preserve operational agility and trial continuity. Flexible supplier contracts and supply chain risk assessments will remain central to avoiding delays and mitigating budgetary pressures.

Methodology & Data Sources

This report integrates comprehensive secondary research, including peer-reviewed articles, regulatory filings, global trial registries, and industry reports. Qualitative insights from expert interviews and data triangulation reinforce validity, while rigorous editorial review ensures the accuracy and objectivity essential for C-suite decisions.

Why This Report Matters

  • Equips executives with a strategic overview of the global cell and gene therapy clinical trial landscape, segmented to support targeted growth and investment decisions.
  • Offers region-by-region intelligence and competitor profiling to optimize site selection, manufacturing strategy, and alliance formation.
  • Provides actionable recommendations to address regulatory shifts, supply chain risks, and workforce capabilities—helping organizations adapt in a complex and dynamic environment.

Conclusion

This report delivers tested, reliable analysis to guide industry leaders through evolving clinical development challenges. Leverage these insights to refine strategies, strengthen competitive positioning, and drive future success in cell and gene therapy trials.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cell & Gene Therapy Clinical Trials Market, by Therapy Type
8.1. Introduction
8.2. Cell Therapy
8.2.1. CAR T Cell
8.2.2. Dendritic Cell Therapy
8.2.3. NK Cell Therapy
8.2.4. Stem Cell Therapy
8.3. Gene Therapy
8.3.1. Non-Viral Vector
8.3.1.1. Electroporation
8.3.1.2. Lipid Nanoparticle
8.3.1.3. Naked DNA/RNA
8.3.2. Viral Vector
8.3.2.1. Adeno-Associated Virus
8.3.2.2. Adenoviral
8.3.2.3. Retroviral
8.4. Tissue Engineered Products
9. Cell & Gene Therapy Clinical Trials Market, by Vector Type
9.1. Introduction
9.2. Non-Viral Vector
9.2.1. Electroporation
9.2.2. Lipid Nanoparticle
9.2.3. Naked DNA/RNA
9.3. Viral Vector
9.3.1. Adeno-Associated Virus
9.3.2. Adenoviral
9.3.3. Retroviral
10. Cell & Gene Therapy Clinical Trials Market, by Cell Type
10.1. Introduction
10.2. Dendritic Cell
10.3. NK Cell
10.4. Stem Cell
10.4.1. Hematopoietic Stem Cell
10.4.2. Mesenchymal Stem Cell
10.5. T Cell
10.5.1. CAR T
10.5.2. TCR
11. Cell & Gene Therapy Clinical Trials Market, by Indication
11.1. Introduction
11.2. Neurology
11.2.1. Alzheimer Disease
11.2.2. Parkinson Disease
11.3. Oncology
11.3.1. Hematologic Cancer
11.3.1.1. Leukemia
11.3.1.2. Lymphoma
11.3.2. Solid Tumor
11.3.2.1. Breast Cancer
11.3.2.2. Melanoma
11.4. Rare Disease
11.4.1. Genetic Disorder
11.4.1.1. Cystic Fibrosis
11.4.1.2. Hemophilia
11.4.2. Metabolic Disorder
12. Cell & Gene Therapy Clinical Trials Market, by Trial Phase
12.1. Introduction
12.2. Phase I
12.3. Phase II
12.4. Phase III
13. Americas Cell & Gene Therapy Clinical Trials Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Cell & Gene Therapy Clinical Trials Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Cell & Gene Therapy Clinical Trials Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Novartis AG
16.3.2. Gilead Sciences, Inc.
16.3.3. Spark Therapeutics, Inc.
16.3.4. bluebird bio, Inc.
16.3.5. Sangamo Therapeutics, Inc.
16.3.6. CRISPR Therapeutics AG
16.3.7. Editas Medicine, Inc.
16.3.8. Fate Therapeutics, Inc.
16.3.9. Orchard Therapeutics Ltd
16.3.10. uniQure N.V.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. CELL & GENE THERAPY CLINICAL TRIALS MARKET MULTI-CURRENCY
FIGURE 2. CELL & GENE THERAPY CLINICAL TRIALS MARKET MULTI-LANGUAGE
FIGURE 3. CELL & GENE THERAPY CLINICAL TRIALS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. CELL & GENE THERAPY CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. CELL & GENE THERAPY CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CELL & GENE THERAPY CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T CELL, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ALZHEIMER DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PARKINSON DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RARE DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENETIC DISORDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENETIC DISORDER, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY METABOLIC DISORDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RARE DISEASE, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RARE DISEASE, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENETIC DISORDER, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RARE DISEASE, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENETIC DISORDER, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 114. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 115. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 116. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 117. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 118. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 119. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 120. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 121. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 122. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 123. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, 2018-2030 (USD MILLION)
TABLE 124. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, 2018-2030 (USD MILLION)
TABLE 125. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 126. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 127. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 128. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, 2018-2030 (USD MILLION)
TABLE 129. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 130. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RARE DISEASE, 2018-2030 (USD MILLION)
TABLE 131. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENETIC DISORDER, 2018-2030 (USD MILLION)
TABLE 132. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 133. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 134. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 135. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 136. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 137. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 138. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 139. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 140. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 141. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 142. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, 2018-2030 (USD MILLION)
TABLE 143. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, 2018-2030 (USD MILLION)
TABLE 144. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 145. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 146. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 147. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, 2018-2030 (USD MILLION)
TABLE 148. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 149. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RARE DISEASE, 2018-2030 (USD MILLION)
TABLE 150. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENETIC DISORDER, 2018-2030 (USD MILLION)
TABLE 151. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 160. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 161. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, 2018-2030 (USD MILLION)
TABLE 162. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, 2018-2030 (USD MILLION)
TABLE 163. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 164. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 165. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 166. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, 2018-2030 (USD MILLION)
TABLE 167. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 168. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RARE DISEASE, 2018-2030 (USD MILLION)
TABLE 169. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENETIC DISORDER, 2018-2030 (USD MILLION)
TABLE 170. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 171. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 172. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 173. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 174. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 175. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 176. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 177. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 178. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 179. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 180. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, 2018-2030 (USD MILLION)
TABLE 181. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, 2018-2030 (USD MILLION)
TABLE 182. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 183. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 184. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 185. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, 2018-2030 (USD MILLION)
TABLE 186. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 187. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RARE DISEASE, 2018-2030 (USD MILLION)
TABLE 188. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENETIC DISORDER, 2018-2030 (USD MILLION)
TABLE 189. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, 2018-2030 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, 2018-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, 2018-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RARE DISEASE, 2018-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENETIC DISORDER, 2018-2030 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 210. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 212. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 214. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 216. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 218. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, 2018-2030 (USD MILLION)
TABLE 220. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, 2018-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 222. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 224. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, 2018-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 226. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RARE DISEASE, 2018-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENETIC DISORDER, 2018-2030 (USD MILLION)
TABLE 228. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 229. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 230. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 231. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 232. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 233. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 234. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 235. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 236. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 237. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 238. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, 2018-2030 (USD MILLION)
TABLE 239. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, 2018-2030 (USD MILLION)
TABLE 240. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 241. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 242. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 243. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, 2018-2030 (USD MILLION)
TABLE 244. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 245. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RARE DISEASE, 2018-2030 (USD MILLION)
TABLE 246. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENETIC DISORDER, 2018-2030 (USD MILLION)
TABLE 247. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 248. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 249. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 250. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 251. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 252. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 253. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 254. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 255. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 256. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 257. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, 2018-2030 (USD MILLION)
TABLE 258. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, 2018-2030 (USD MILLION)
TABLE 259. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 260. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 261. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 262. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, 2018-2030 (USD MILLION)
TABLE 263. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 264. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RARE DISEASE, 2018-2030 (USD MILLION)
TABLE 265. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENETIC DISORDER, 2018-2030 (USD MILLION)
TABLE 266. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 267. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 268. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 269. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 270. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 271. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 272. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 273. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 274. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 275. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 276. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, 2018-2030 (USD MILLION)
TABLE 277. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, 2018-2030 (USD MILLION)
TABLE 278. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 279. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 280. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 281. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, 2018-2030 (USD MILLION)
TABLE 282. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
TABLE 283. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RARE DISEASE, 2018-2030 (USD MILLION)
TABLE 284. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENETIC DISORDER, 2018-2030 (USD MILLION)
TABLE 285. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2030 (USD MILLION)
TABLE 286. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 287. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 288. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 289. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 290. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 291. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 292. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 293. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-20

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Cell & Gene Therapy Clinical Trials market report include:
  • Novartis AG
  • Gilead Sciences, Inc.
  • Spark Therapeutics, Inc.
  • bluebird bio, Inc.
  • Sangamo Therapeutics, Inc.
  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • Fate Therapeutics, Inc.
  • Orchard Therapeutics Ltd
  • uniQure N.V.

Table Information

Report AttributeDetails
No. of Pages181
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 12.08 Billion
Forecasted Market Value ( USD ) by 2030 $ 23.95 Billion
Compound Annual Growth Rate14.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Cancer Gene Therapy Market by Vector Type, Therapy Type, Indication, Stage, End User - Global Forecast to 2030 - Product Image

Cancer Gene Therapy Market by Vector Type, Therapy Type, Indication, Stage, End User - Global Forecast to 2030

  • Report
  • 183 Pages
  • Global
From
Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Acute Lymphoblastic Leukemia, Large B-cell Lymphoma), By Vector Type (Lentivirus), By Route Of Administration, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Acute Lymphoblastic Leukemia, Large B-cell Lymphoma), By Vector Type (Lentivirus), By Route Of Administration, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 120 Pages
  • Global
From
Cell & Gene Therapy Market by Therapy Type, Delivery Method, Therapeutic Areas, Application, End User - Global Forecast to 2030 - Product Image

Cell & Gene Therapy Market by Therapy Type, Delivery Method, Therapeutic Areas, Application, End User - Global Forecast to 2030

  • Report
  • 192 Pages
  • Global
From
Gene Therapy Market Outlook to 2029 - Product Image

Gene Therapy Market Outlook to 2029

  • Report
  • 83 Pages
  • Global
From
Gene Therapy Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F - Product Image

Gene Therapy Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F

  • Report
  • 187 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.